Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Acute Lymphoblastic Leukemia
- Lymphoma
- Pediatric ALL
- Pediatric Cancer
- Pediatric Lymphoma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: RandomizedIntervention Model: Crossover AssignmentIntervention Model Description: The study uses a prospective randomized controlled crossover study design.Masking: None (Open Label)Primary Purpose: Supportive Care
Participation Requirements
- Age
- Between 1 years and 17 years
- Gender
- Both males and females
Description
This study uses a prospective randomized controlled crossover study design. Neither patients nor clinicians are blinded to the standard versus reduced intravenous fluids (IVF) regimen. Patients are randomized to begin with standard volume or reduced volume IVF. Over the course of 4 cycles of High Do...
This study uses a prospective randomized controlled crossover study design. Neither patients nor clinicians are blinded to the standard versus reduced intravenous fluids (IVF) regimen. Patients are randomized to begin with standard volume or reduced volume IVF. Over the course of 4 cycles of High Dose Methotrexate (HDMTX), patients alternate between standard and reduced volume post hydration fluids protocols.
Tracking Information
- NCT #
- NCT03964259
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Cady P Noda, PharmD Virginia Commonwealth University
Get Well Soon